oxitropium
Trade name: Oxivent
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 1998 (NCT02182661)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M2ANTAGONIST
CHRM2 antagonist
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ba253
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02182583 | Phase 3 | Oct 1, 1998 | Boehringer Ingelheim |
| NCT02182635 | Phase 3 | Aug 1, 1998 | Boehringer Ingelheim |
| NCT02182661 | Phase 3 | Jul 1, 1998 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 1998 |
1 organizations
Page 1 / 1